Citius Pharmaceuticals, Inc. (CTXR) Key Metrics
CTXR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $12.6M
- Enterprise value
- $5.8M
- P/E (TTM)
- —
- Forward P/E
- 0.3
- PEG ratio
- —
- Price / sales
- 1.8
- Price / book
- 0.2 10-yr median 1.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.00
CTXR key metrics, FY2016–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsCTXR valuation Price multiples at each fiscal year-end price.
CTXR returns How much profit the business earns on the capital it uses.
CTXR per-share figures Results divided by the shares outstanding at year-end.
CTXR financial health Debt, liquidity and how easily interest is covered.
CTXR efficiency & capital use Working capital cycle and where the cash goes.
CTXR valuation history
CTXR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CTXR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CTXR price vs earnings per share
CTXR key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $13.7M | $145.2M | $103.5M | $176.8M | — | — | — | — | — | — |
| Enterprise value | $11.3M | $142.2M | $77.5M | $135.7M | — | — | — | — | — | — |
| Price / book | 0.2 | 2.1 | 1.1 | 1.7 | — | — | — | — | — | — |
| Earnings yield | −272.8% | −27.0% | −31.4% | −19.0% | — | — | — | — | — | — |
| Free cash flow yield | −193.5% | −19.4% | −28.1% | −16.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.24 | $12.53 | $17.10 | $30.25 | $50.75 | $26.00 | $18.95 | $42.75 | $78.83 | $236.25 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$3.38 | −$3.38 | −$5.38 | −$5.76 | — | — | — | — | — | — |
| Operating cash flow per share | −$2.40 | −$2.43 | −$4.80 | −$4.85 | — | — | — | — | — | — |
| Free cash flow per share | −$2.40 | −$2.43 | −$4.80 | −$4.85 | — | — | — | — | — | — |
| Cash per share | $0.38 | $0.28 | $4.38 | $7.14 | — | — | — | — | — | — |
| Book value per share | $6.10 | $6.05 | $15.01 | $17.60 | — | — | — | — | — | — |
| Tangible book value per share | −$3.13 | −$2.77 | $3.65 | $5.83 | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Debt per share | $0.16 | $0.02 | $0.08 | $0.12 | — | — | — | — | — | — |
| Shares outstanding | 11.1M | 11.6M | 6.1M | 5.8M | — | — | — | — | — | — |
| Change in shares outstanding | −4.5% | +91.5% | +3.6% | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −54.4% | −48.6% | −33.6% | −28.6% | −27.8% | −60.5% | −59.6% | −50.3% | −53.6% | −102.9% |
| Return on invested capital (ROIC) | −46.0% | −50.3% | −45.8% | −42.2% | −44.2% | −74.0% | −69.4% | −57.7% | −43.8% | −71.0% |
| Return on assets (ROA) | −30.2% | −35.5% | −29.9% | −26.2% | −24.8% | −48.2% | −51.9% | −45.2% | −44.8% | −73.1% |
| Return on tangible assets | −130.0% | −269.8% | −93.3% | −74.3% | −31.3% | −116.8% | −194.7% | −124.6% | −302.8% | −861.0% |
| Financial health | ||||||||||
| Total debt | $1.8M | $262,865 | $481,245 | $678,234 | $855,471 | $1.4M | $172,970 | $172,970 | $172,970 | $672,970 |
| Cash & short-term investments | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M | $13.9M | $7.9M | $9.2M | $3.2M | $294,351 |
| Net debt | −$2.4M | −$3.0M | −$26.0M | −$41.0M | −$69.2M | −$12.5M | −$7.7M | −$9.0M | −$3.0M | $378,619 |
| Debt / equity | 0.03 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 | 0.01 | 0.01 | 0.01 | 0.04 |
| Debt / assets | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 |
| Current ratio | 0.62 | 0.40 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 |
| Quick ratio | 0.13 | 0.17 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 |
| Interest coverage | -143.9 | — | — | -132.5 | — | — | -948.6 | -870.6 | -11.7 | -828.3 |
| Working capital | −$17.0M | −$21.6M | $28.6M | $40.0M | $68.8M | $9.9M | $3.3M | $6.9M | $955,189 | −$4.3M |
| Invested capital | $65.1M | $67.1M | $64.8M | $61.8M | $63.0M | $21.2M | $16.7M | $18.9M | $18.9M | $17.1M |
| Tangible asset value | −$24.6M | −$28.0M | $22.7M | $34.7M | $64.0M | $4.9M | $3.4M | $6.9M | $960,592 | −$4.2M |
| Net current asset value | −$25.5M | −$28.3M | $22.2M | $34.0M | $63.2M | $3.9M | $3.3M | $6.9M | $955,189 | −$4.3M |
| Graham net-net per share | −$3.44 | −$3.03 | $2.36 | $5.33 | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 242.66 | 0.01 | 2.05 | 1.04 | 0.81 | 1.58 |
| Efficiency | ||||||||||
| Days of inventory on hand | 26,027.4 | 7,199.3 | — | — | — | — | — | — | — | — |
| Days payables outstanding | 15,861.4 | 6,838.6 | 3,843.8 | 2,480.8 | 3,468.4 | 5,473.6 | 876,119.8 | 226,524.4 | 104,811.8 | 199,527.8 |
| Receivables turnover | — | — | — | — | — | — | — | 0.00 | — | — |
| Payables turnover | 0.02 | 0.05 | 0.09 | 0.15 | 0.11 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | 0.01 | 0.05 | — | — | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | — | — | — | $818,343 | — | — |
| Average payables | $9.3M | $3.9M | $2.0M | $1.2M | $1.6M | $2.3M | $2.1M | $1.1M | $755,794 | $734,153 |
| Average inventory | $15.3M | $4.1M | $0 | — | — | — | — | — | — | — |
| Intangibles / total assets | 78.0% | 87.6% | 66.4% | 60.3% | 48.3% | 65.7% | 72.4% | 67.6% | 86.0% | 95.6% |
Computed from CTXR's annual financial statements (latest annual report filed December 23, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CTXR valuation and financial ratios
Citius Pharmaceuticals earned a return on equity of −54.4% and a return on invested capital of −46.0% in fiscal 2025. It ended the year with $1.8 million of debt and $4.3 million in cash and short-term investments, a net cash position of $2.4 million.
See the CTXR income statement, the CTXR chart for price history, or the CTXR stock overview for the latest quote and news.
CTXR key metrics FAQ
What is Citius Pharmaceuticals's return on equity?
Citius Pharmaceuticals's return on equity (ROE) was −54.4% in fiscal 2025: net income of -$37.4 million on average shareholders' equity of $68.8 million.
What is Citius Pharmaceuticals's ROIC?
Citius Pharmaceuticals's return on invested capital was −46.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Citius Pharmaceuticals have?
Citius Pharmaceuticals had total debt of $1.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Citius Pharmaceuticals's free cash flow yield?
Citius Pharmaceuticals generated -$26.6 million of free cash flow in fiscal 2025, a free cash flow yield of −193.5% on its market value at year-end ($13.7 million).
What is Citius Pharmaceuticals's current ratio?
Citius Pharmaceuticals's current ratio was 0.62 at the end of fiscal 2025: current assets were 0.62 times current liabilities.